Kura Oncology to Report Second Quarter 2024 Financial Results
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. financial markets close. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and provide a corporate update.
Interested parties can access the live call by dialing (877) 300-8521 (domestic) or (412) 317-6026 (international). A live webcast and archived replay of the event will be available on the company's website at www.kuraoncology.com in the investor relations section.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, KURA declined 2.98%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2024 financial results after the close of U.S. financial markets on Thursday, August 8, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (877) 300-8521 for domestic callers and (412) 317-6026 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Alexandra Weingarten
Associate Director, Investor Relations &
Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When will Kura Oncology (KURA) report its Q2 2024 financial results?
How can investors access Kura Oncology's (KURA) Q2 2024 earnings call?
What time is Kura Oncology's (KURA) Q2 2024 earnings call scheduled for?
Where can I find the replay of Kura Oncology's (KURA) Q2 2024 earnings call?
